Cogent Biosciences Inc (COGT) has a current Price-to-Book (P/B) ratio of 24.98. Compared to its 3-year average P/B ratio of 7.63, the current P/B ratio is approximately 227.33% higher. Relative to its 5-year average P/B ratio of 5.73, the current P/B ratio is about 336.04% higher. Cogent Biosciences Inc (COGT) has a Forward Free Cash Flow (FCF) yield of approximately -4.67%. Compared to its 3-year average FCF yield of -19.78%, the current FCF yield is approximately -76.40% lower. Relative to its 5-year average FCF yield of -18.13%, the current FCF yield is about -74.24% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for COGT competitors is 210.66, providing a benchmark for relative valuation. Cogent Biosciences Inc Corp (COGT.O) exhibits a P/S ratio of 886.56, which is 320.85% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of COGT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of COGT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is COGT currently overvalued or undervalued?

What is Cogent Biosciences Inc (COGT) fair value?

COGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cogent Biosciences Inc (COGT) is between to according to relative valuation method.

How does COGT's valuation metrics compare to the industry average?

The average P/S ratio for COGT's competitors is 210.66, providing a benchmark for relative valuation. Cogent Biosciences Inc Corp (COGT) exhibits a P/S ratio of 886.56, which is 320.85% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Cogent Biosciences Inc (COGT) as of Mar 02 2026?

As of Mar 02 2026, Cogent Biosciences Inc (COGT) has a P/B ratio of 24.98. This indicates that the market values COGT at 24.98 times its book value.

What is the current FCF Yield for Cogent Biosciences Inc (COGT) as of Mar 02 2026?

As of Mar 02 2026, Cogent Biosciences Inc (COGT) has a FCF Yield of -4.67%. This means that for every dollar of Cogent Biosciences Inc's market capitalization, the company generates -4.67 cents in free cash flow.

What is the current Forward P/E ratio for Cogent Biosciences Inc (COGT) as of Mar 02 2026?

As of Mar 02 2026, Cogent Biosciences Inc (COGT) has a Forward P/E ratio of -17.41. This means the market is willing to pay $-17.41 for every dollar of Cogent Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cogent Biosciences Inc (COGT) as of Mar 02 2026?

As of Mar 02 2026, Cogent Biosciences Inc (COGT) has a Forward P/S ratio of 886.56. This means the market is valuing COGT at $886.56 for every dollar of expected revenue over the next 12 months.

COGT Valuation